DCcov: Repositioning of drugs and drug combinations for SARS-CoV-2 infected lung through constraint-based modeling
Summary: The 2019 coronavirus disease (COVID-19) became a worldwide pandemic with currently no approved effective antiviral drug. Flux balance analysis (FBA) is an efficient method to analyze metabolic networks. Here, FBA was applied on human lung cells infected with severe acute respiratory syndrom...
Guardado en:
Autores principales: | Ali Kishk, Maria Pires Pacheco, Thomas Sauter |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d4b8d6e3557e45218daa87b84f6a4c37 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
por: Francisco J. Zapatero-Belinchón, et al.
Publicado: (2021) -
Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells
por: Ria Goswami, et al.
Publicado: (2021) -
SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera
por: Alona Kuzmina, et al.
Publicado: (2021) -
Endonuclease-based genotyping of the RBM as a method to track the emergence or evolution of SARS-CoV-2 variants
por: Eva Lopez, et al.
Publicado: (2021) -
Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease
por: Bryce M. Warner, et al.
Publicado: (2021)